Results 171 to 180 of about 51,662 (290)

What Is New in Cutaneous T Cell Lymphoma? [PDF]

Curr Oncol Rep, 2023
Morgenroth S, Roggo A, Pawlik L, Dummer R, Ramelyte E.   +4 more
europepmc   +1 more source

Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review

Photochemistry and Photobiology, EarlyView.
Conventional treatments for various types of cancer are often associated with tumor recurrence and aggressiveness. Photobiomodulation with blue light (BL; 450–470 nm) emerges as a promising alternative with antitumor effects. This systematic review, with 37 in vitro and in vivo studies from 2002 to 2024, revealed that BL reduces cell viability ...
Bárbara Evelyn Santos de Lima, Rebeca Barros Nascimento, Ana Paula Mariano Santos Ginez, Maria Stella Moreira, Rebeca Boltes Cecatto, Rodrigo Labat Marcos, Maria Fernanda Setúbal Destro Rodrigues   +6 more
wiley   +1 more source

Recurrence of mogamulizumab-associated rash in patients with relapsed erythrodermic cutaneous T-cell lymphoma after retreatment with mogamulizumab. [PDF]

JAAD Case Rep
McIntyre ER, Crisan L, Zain J, Querfeld C.   +3 more
europepmc   +1 more source

Overall and Cause-Specific Mortality Among Patients With Cutaneous T-Cell Lymphoma in the United States. [PDF]

EJHaem
Shea L, Narkhede M, Chamarti K, Gao T, Mehta A, Goyal G.   +5 more
europepmc   +1 more source

Immunopathogenesis and therapy of cutaneous T cell lymphoma [PDF]

, 2007
Eun Ji Kim, S. Hess, Stewart K. Richardson, Samuel D. Newton, L. C. Showe, B. M. Benoit, R. Ubriani, C. C. Vittorio, J. M. Junkins-Hopkins, M. Wysocka, A. H. Rook   +10 more
openalex   +1 more source

Extracorporeal photopheresis—New insights into an old procedure

Transfusion Medicine, EarlyView.
Abstract Background Extracorporeal photopheresis (ECP) is a safe immunomodulatory strategy that induces cell‐type selective apoptosis through photodynamic processes. Despite decades of use, the mechanisms underlying ECP remain largely unexplored, particularly in studies examining specific immune cell subsets in ex vivo setups.
Sabine Seiffert, Janine Kirchberg, Enrica Bach, Victoria Menger, Mandy Brückner, Ulrich Sack, Ulrike Köhl, Uwe Platzbecker, Andreas Boldt, Marco Herling, Vladan Vučinić   +10 more
wiley   +1 more source

Drug- and Vaccine-Induced Cutaneous T-Cell Lymphoma: A Systematic Review of the Literature. [PDF]

J Skin Cancer
Etesami I, Ansari MS, Pourgholi E, Heidari S, Rafati A, Bahramian S, Danaei B, Demokri S, Fazeli P, Memari H, Mirzaee Godarzee H, Sadeghi B, Vahabi SM.   +12 more
europepmc   +1 more source

Incidence trends of primary cutaneous B‐ and T‐cell lymphoma before and after the COVID‐19 pandemic [PDF]

Ioannis‐Alexios Koumprentziotis, Aikaterini Niforou, Stella Kaliampou, Antonios Tsimpidakis, Maria Gerochristou, Leonidas Marinos, Alexander Stratigos, Evangelia Papadavid, Vasiliki Nikolaou   +8 more
openalex   +1 more source

Evaluating VEGFR2 as a Target for Anti‐Tumour Therapy in Canine Melanoma

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Vascular endothelial growth factor receptor 2 (VEGFR2) is a key target for anti‐angiogenic oncotherapy, as inhibiting this receptor on tumour vasculature slows tumour development and enhances drug‐ and immune infiltration, improving therapy outcome.
Esther Hindriks, Wilhelmina Bergmann, Aitor Martínez Ruiz, Maurice M. J. M. Zandvliet, Alice J. A. M. Sijts, Femke Broere   +5 more
wiley   +1 more source

CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention. [PDF]

Leukemia
Isabelle C, Boles A, McConnell K, Keller R, Burzinski R, Hutchins Z, Calabretto G, Cheslow L, Xu J, Chakravarti N, Porcu P, Nikbakht N, Mishra A.   +12 more
europepmc   +1 more source